Eli Lilly signed a new China-focused partnership with Beijing-based InnoCare, a deal that could reach up to $3.35 billion if products reach the market. Lilly will provide upfront funding and near-term payments, while InnoCare will apply its in-house discovery capabilities to generate new medicine candidates. The transaction reinforces Lilly’s strategy of repeatedly adding China alliances since January 2025, signaling a sustained commitment to regional pipelines and discovery execution where local platform partners can move faster. For biotech industry players, the pact is a reminder that China dealmaking remains active even as global R&D competition intensifies. The scale and multi-target framing also indicate that Lilly is continuing to prioritize breadth in early discovery collaborations, leaving room for later portfolio selection and licensing moves.